[7] Packer M.(2020). SGLT2 Inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: A paradigm shift in understanding their mechanism of action, Diabetes Care, 43(3), 508–511. https://doi.org/10.2337/dci19-0074 [8] Packer ...
SGLT2抑制剂引起的酮症酸中毒-机制篇 SGLT2抑制剂(SGLT2i)是一类通过抑制钠-葡萄糖协同转运蛋白2,降低机体对葡萄糖的重吸收,从而增加尿糖排出的降糖药物。2015年5月,FDA发出警告称[1],使用SGLT2i治疗2型糖尿病可能会引起酮症酸中毒。 SGLT2i引起酮症酸中毒的机...
2.SGLT2Inhibitor Diabetes Drugs May Cause Ketoacidosis: FDA. Medscape. May 15, 2015. 3. OgawaW, SakaguchiK. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors[J]. J Diabetes Investig, 2016, 7(...
参考文献: [1]SGLT2 Inhibitor Diabetes Drugs May Cause Ketoacidosis[S]:FDA.Medscape.May 15, 2015. [2]EMA on Lowering Risk of Diabetic Ketoacidosis With SGLT2Inhibitors.Medscape.Feb 12, 2016. [3]Douros A, Lix LM, Fralick M,et al. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk fo...
(ns-MRAs), there are multiple variations of medications suited to treat chronic kidney disease (CKD). However, when it comes to the beginning of a CKD medication regimen, experts believe sodium-glucose cotransporter-2 (SGLT) inhibitors are the standard medications for patients with CKD and an ...
1. Madaan, Tushar,Akhtar, Mohd., Najmi, Abul Kalam, Sodium glucose CoTransporter 2 (SGLT2)inhibitors: Current status and future perspective, (2016), doi:10.1016/j.ejps.2016.08.025 2. A new class ofdrugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity.Journal of Cardiology...
ketoacidosis, SGLT2 inhibitors like Invokana and Farxiga have been tied to an increased risk of kidney failure, and in a recent report issued by the Institute for Safe Medication Practices (ISMP), the agency identified several red flags regarding SGLT2 inhibitors drugs and kidney toxicity ...
SGLT2 inhibitors improve hyperglycemia with a decline in body weight and blood pressure, the outcomes touted to be of major importance in management of type 2 diabetes. However, the efficacy in lowering glycemia is very modest and imparts an undue cost burden on patients. Moreover, the ...
编者按:近期,由北京白求恩公益基金会发起,多位内分泌领域核心专家牵头撰写完成的《钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)联合二甲双胍治疗2型糖尿病(T2DM)专家共识》(以下简称“共识”)发表于《国际内分泌代谢杂志》。这是中国首个专门针对SGLT2i联合二甲双胍治疗T2DM临床应用的指导性文件,为临床医生了解并规...
1. Madaan, Tushar,Akhtar, Mohd., Najmi, Abul Kalam, Sodium glucose CoTransporter 2 (SGLT2)inhibitors: Current status and future perspective, (2016), doi:10.1016/j.ejps.2016.08.025 2. A new class ofdrugs for heart failure:...